KDM5D Knockout T-47D Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the T-47D human breast ductal carcinoma cell line, engineered to disrupt the KDM5D gene. This polyclonal pool contains a heterogeneous mix of edited cells, each carrying distinct modification events at the target locus, resulting in loss of functional KDM5D protein. The product provides a versatile loss-of-function model for investigating the epigenetic regulatory roles of KDM5D in hormone-responsive breast cancer cells.
The T-47D host cell line was originally established from a pleural effusion of a patient with metastatic infiltrating ductal carcinoma of the breast and is widely used as a model for hormone-responsive breast cancer. These cells express estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR), and maintain key signaling pathways responsive to steroid hormones. Their epithelial origin and hormone receptor positivity make them particularly valuable for studying luminal-type breast cancer biology, endocrine therapy resistance, and hormone-dependent gene regulation.
KDM5D is a histone lysine demethylase that specifically removes methyl groups from di- and tri-methylated histone H3 at lysine 4 (H3K4me2/3), converting them to the monomethylated or unmethylated state and thereby functioning as a transcriptional repressor. KDM5D interacts with retinoblastoma-associated protein (RB), histone deacetylases HDAC1 and HDAC2, and the SIN3A corepressor complex, which together reinforce repressive chromatin environments. Upstream regulation can involve transcription factors such as SOX9 and epigenetic silencing through promoter methylation, while downstream targets include genes marked by H3K4me3, such as PRM1 and TNP1, and potentially other promoters sensitive to H3K4 methylation dynamics. The demethylase activity of KDM5D directly alters the chromatin landscape, leading to gene silencing events that impact cellular processes including proliferation and differentiation.
In T-47D cells, disruption of KDM5D provides a unique resource to dissect how histone demethylation influences the epigenetic and transcriptional landscape of hormone-responsive breast cancer. Loss of this repressive demethylase is expected to increase global H3K4me2/3 levels at target promoters, potentially reactivating genes that may be important in cell proliferation, differentiation, or hormone signaling. Given the crosstalk between epigenetic modifiers and nuclear hormone receptors, this knockout system enables exploration of interactions between androgen/estrogen receptor signaling and chromatin regulation. The polyclonal nature of the product mirrors the heterogeneity of tumor cell populations and supports robust evaluation of loss-of-function phenotypes.
Researchers can employ KDM5D Knockout T-47D Polyclonal Cells in a wide range of functional and mechanistic studies. Common applications include analyzing changes in global and locus-specific histone methylation by ChIP-qPCR for H3K4me3, profiling transcriptomic alterations via RNA-seq, and validating target gene expression through RT-qPCR. Western blotting confirms loss of KDM5D protein. The cells are also suitable for phenotypic assays such as cell proliferation, migration, and invasion, as well as drug sensitivity tests to assess the role of KDM5D in therapeutic response. For further assistance with experimental design or to discuss custom services, please contact Ascent Research.
